Logo image of ATHA

ATHIRA PHARMA INC (ATHA) Stock Price, Quote, News and Overview

NASDAQ:ATHA - Nasdaq - US04746L1044 - Common Stock - Currency: USD

0.304  -0.01 (-1.78%)

After market: 0.3182 +0.01 (+4.67%)

ATHA Quote, Performance and Key Statistics

ATHIRA PHARMA INC

NASDAQ:ATHA (6/13/2025, 8:00:01 PM)

After market: 0.3182 +0.01 (+4.67%)

0.304

-0.01 (-1.78%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High3.67
52 Week Low0.22
Market Cap11.87M
Shares39.04M
Float30.29M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30
IPO09-18 2020-09-18


ATHA short term performance overview.The bars show the price performance of ATHA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

ATHA long term performance overview.The bars show the price performance of ATHA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ATHA is 0.304 USD. In the past month the price increased by 8.92%. In the past year, price decreased by -88.03%.

ATHIRA PHARMA INC / ATHA Daily stock chart

ATHA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.55 776.54B
JNJ JOHNSON & JOHNSON 15.63 377.99B
NVO NOVO-NORDISK A/S-SPONS ADR 21.87 354.71B
NVS NOVARTIS AG-SPONSORED ADR 14.37 235.92B
AZN ASTRAZENECA PLC-SPONS ADR 16.91 230.73B
MRK MERCK & CO. INC. 10.49 205.18B
PFE PFIZER INC 7.64 139.52B
SNY SANOFI-ADR 10.99 120.88B
BMY BRISTOL-MYERS SQUIBB CO 6.78 101.25B
GSK GSK PLC-SPON ADR 9.14 82.81B
ZTS ZOETIS INC 27.3 73.16B
HLN HALEON PLC-ADR 21.74 48.91B

About ATHA

Company Profile

ATHA logo image Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

Company Info

ATHIRA PHARMA INC

18706 North Creek Parkway, Suite 104, Box 352141

Bothell WASHINGTON 98011 US

CEO: Leen Kawas

Employees: 26

ATHA Company Website

ATHA Investor Relations

Phone: 14256208501

ATHIRA PHARMA INC / ATHA FAQ

What is the stock price of ATHIRA PHARMA INC today?

The current stock price of ATHA is 0.304 USD. The price decreased by -1.78% in the last trading session.


What is the ticker symbol for ATHIRA PHARMA INC stock?

The exchange symbol of ATHIRA PHARMA INC is ATHA and it is listed on the Nasdaq exchange.


On which exchange is ATHA stock listed?

ATHA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ATHIRA PHARMA INC stock?

8 analysts have analysed ATHA and the average price target is 0.41 USD. This implies a price increase of 34.21% is expected in the next year compared to the current price of 0.304. Check the ATHIRA PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ATHIRA PHARMA INC worth?

ATHIRA PHARMA INC (ATHA) has a market capitalization of 11.87M USD. This makes ATHA a Nano Cap stock.


How many employees does ATHIRA PHARMA INC have?

ATHIRA PHARMA INC (ATHA) currently has 26 employees.


What are the support and resistance levels for ATHIRA PHARMA INC (ATHA) stock?

ATHIRA PHARMA INC (ATHA) has a resistance level at 0.34. Check the full technical report for a detailed analysis of ATHA support and resistance levels.


Should I buy ATHIRA PHARMA INC (ATHA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ATHIRA PHARMA INC (ATHA) stock pay dividends?

ATHA does not pay a dividend.


When does ATHIRA PHARMA INC (ATHA) report earnings?

ATHIRA PHARMA INC (ATHA) will report earnings on 2025-07-30.


What is the Price/Earnings (PE) ratio of ATHIRA PHARMA INC (ATHA)?

ATHIRA PHARMA INC (ATHA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.07).


What is the Short Interest ratio of ATHIRA PHARMA INC (ATHA) stock?

The outstanding short interest for ATHIRA PHARMA INC (ATHA) is 2.48% of its float. Check the ownership tab for more information on the ATHA short interest.


ATHA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ATHA. When comparing the yearly performance of all stocks, ATHA is a bad performer in the overall market: 95.8% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ATHA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ATHA. ATHA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ATHA Financial Highlights

Over the last trailing twelve months ATHA reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 32.13% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -183.27%
ROE -213.62%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.67%
Sales Q2Q%N/A
EPS 1Y (TTM)32.13%
Revenue 1Y (TTM)N/A

ATHA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 48% to ATHA. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners36.76%
Ins Owners2.93%
Short Float %2.48%
Short Ratio2.14
Analysts
Analysts47.5
Price Target0.41 (34.87%)
EPS Next Y69.96%
Revenue Next YearN/A